WOONSOCKET, R.I. — A proposal within the Tennessee legislature might drive CVS Well being to sever a core piece of its enterprise mannequin or exit the state fully, and it’s rising as a key check of how far lawmakers nationally is likely to be keen to go to rein in pharmacy profit managers.
Pharmacy profit managers, or PBMs, play a key position negotiating drug costs, processing pharmacy claims, dealing with prescription authorizations, and managing drug advantages for well being insurers and employers. Along with proudly owning roughly 9,000 retail pharmacy areas throughout the US, CVS Well being owns Aetna, a well being insurer, and Caremark, a PBM.
The Tennessee invoice would prohibit a single firm from proudly owning each a retail pharmacy and a pharmacy profit supervisor. If enacted, Woonsocket, R.I.-based CVS says it might shut greater than 130 shops in Tennessee, placing greater than 2,000 jobs in danger.
Most reforms to this point have targeted on pricing practices and transparency. However the invoice in Tennessee, which has additionally been mirrored in different states, goes additional, making an attempt to separate the entities that negotiate drug costs from those who dispense them.
Tennessee state Senator Bobby Harshbarger, a pharmacist and Republican who sponsored this newest invoice, instructed the Globe the laws addresses a “structural battle within the pharmacy market.”
“This laws separates pharmacy profit managers from proudly owning or controlling the pharmacies they reimburse or steer sufferers towards,” Harshbarger mentioned in a press release. Pharmacies that personal PBMs would want to divest from them to adjust to the laws, he mentioned, however “it doesn’t remove PBMs, shut pharmacies, or cut back entry to medicines.”
CVS argues that sort of separation is just not possible. A spokeswoman mentioned there isn’t a apparent purchaser for its pharmacies in Tennessee.
“When Ceremony Assist filed for chapter, CVS Pharmacy was one of many solely pharmacies to purchase and function closing Ceremony Assist shops” in Tennessee, mentioned firm spokesperson Amy Thibault. “It’s unlikely one other pharmacy might or would purchase 134 CVS pharmacies, or the others impacted by the invoice.”
This invoice is “unhealthy for Tennessee, for the greater than 1.5 million sufferers we serve, and for the greater than 2,000 colleagues who will lose good paying jobs,” added Thibault.
Authorized consultants mentioned having PBMs and pharmacies owed by the identical firm restricts worth competitors and hurts shoppers.
“When one firm is negotiating drug costs and owns the pharmacy that fills the prescriptions, they’ve the flexibility to manage each ends of the transaction,” mentioned Robert Tsigler, an lawyer of the Legislation Workplaces of Robert Tsigler in New York, who has years of expertise on either side of the courtroom involving federal and regulatory issues in New York and New Jersey.
However Greg Lopes, a vice chairman for the Pharmaceutical Care Administration Affiliation, a nationwide commerce affiliation representing pharmacy profit managers, referred to as the Tennessee invoice “harmful for sufferers’ well being” and mentioned the coverage wouldn’t truly decrease drug costs.
Lopes pointed to a examine by Moiz Bhai, an economics professor on the College of Arkansas at Little Rock, that urged payments just like the one in Tennessee might drive mass pharmacy closures, enhance drug prices nationwide by practically $32 billion, and result in 44,000 extra hospitalizations. Bhai instructed the Globe that the Pharmaceutical Care Administration Affiliation funded the examine.
Tennessee is just not the one state shifting to separate pharmacies and PBMs.
Final 12 months, Arkansas handed a first-in-the-nation legislation to ban PBMs from having an possession curiosity in a pharmacy. CVS filed a lawsuit to dam that legislation, which the corporate mentioned would have shut down 23 of its shops. The legislation has been stayed as a result of a federal decide granted a preliminary injunction to cease its implementation.
New York, Vermont, Texas, and Indiana all have critical legislative efforts to sever PBMs from pharmacy possession underway. Louisiana commissioned a proper examine, and bipartisan federal laws has existed in each chambers.
“This has turn out to be a mainstream place, not a Tennessee-specific dialogue,” mentioned Kelly Prymicz, the vice chairman of MacroHealth, a Washington-based firm that works with insurers and well being methods.
Massachusetts state Senator Cindy F. Friedman, the chairperson of the Well being Care Finance Committee, believes the Tennessee invoice is “an attention-grabbing proposal,“ her spokesperson, Stephen Acosta, mentioned in an electronic mail Wednesday.
”From her perspective any laws that would cut back the affect a PBM has on a affected person’s pockets is price taking a look at, particularly as we see all the pieces PBMs are doing with charges, assessments, and hidden clawbacks,” he mentioned.
In late 2024, the Home Judiciary Committee opened an investigation into doable anticompetitive practices by CVS Caremark, searching for to look at the corporate’s relationship with pharmaceutical hubs, third-party on-line providers designed to streamline affected person entry to complicated specialty remedy and enhance worth transparency. Earlier this 12 months, the committee introduced it discovered that CVS Well being could have violated federal antitrust legal guidelines by threatening unbiased pharmacies to maintain them from utilizing money-saving providers exterior Caremark.
The “large three” PBMs — CVS Caremark, Cigna’s Categorical Scripts, and UnitedHealth’s OptumRx — management roughly 60 % of the market. A Federal Commerce Fee report launched in January discovered that these three corporations had generated billions of {dollars} in income by mountaineering the price of sure medicines, together with these used to deal with coronary heart illness and most cancers.
PBMs have drawn bipartisan scrutiny because the Trump administration, Congress, and states are searching for methods to decrease costs on prescribed drugs. Over the past decade, lawmakers have devoted vital consideration to the enterprise practices of PBMs, and within the final 12 months, 63 payments overhauling the trade handed in 18 states, in line with the Nationwide Convention of State Legislatures. Nevertheless, not one of the reforms that concentrate on separating pharmacies and PBMs owned by the identical firm have been enacted.
“Whereas threats of CVS pharmacy closures are challenged with assertations of fear-mongering, the implications of this invoice are actually unknown,” mentioned Catherine Cooke, a analysis professor on the College of Maryland’s Faculty of Pharmacy.
Rhode Island, the place CVS is headquartered, is taking a a lot softer strategy. Lawmakers this 12 months have launched a bundle of payments that concentrate on the transparency, oversight, and the state examine of drug prices. However the bundle lacks any form of reform round CVS’s enterprise mannequin.
When requested why Rhode Island wouldn’t go so far as the invoice in Tennessee, Senate President Val Lawson instructed the Globe, “We’re not exploring that in any respect.”
In truth, Lawson mentioned CVS representatives got a heads up earlier than lawmakers launched the payments, and members of her coverage crew mentioned the contents with them.
“I feel it’s helpful to each events,” Lawson mentioned of Rhode Island’s PBM laws.
Rhode Island speaker Okay. Joseph Shekarchi, who can be a full-time lawyer, filed a class-action lawsuit within the US District Courtroom of Rhode Island on Wednesday on behalf of Roofers’ Unions Welfare Belief Fund, alleging that CVS operated a RICO enterprise because it pertains to the company’s PBM contracts.
The criticism claims CVS operated PBM contracts “that falsely and/or misleadingly conceal Caremark’s facet agreements with the drug corporations that take part within the PBM Fraud Enterprises to present favorable formulary placements in return for bribes and kickbacks to Defendants via Zinc.” Zinc Well being Providers is a gaggle buying group established in 2020 by CVS to assist negotiate drug rebates with producers on behalf of Caremark.
Shelly Bendit, a CVS spokesperson, mentioned Thursday that the lawsuit didn’t have any benefit.
“CVS Caremark is dedicated to reducing prescription drug prices for our purchasers and their members via negotiations with pharmaceutical producers,” mentioned Bendit. “We intend to vigorously defend towards these claims.”
However the debate taking part in out a whole lot of miles away might have outsize implications for CVS, and the sufferers who depend upon its pharmacies.
“CVS is a billion-dollar-a-year PBM with huge operations throughout the US,” mentioned Kent McKinney, a well being care economist at Columbia College and former govt at Johnson & Johnson.
Dropping its Tennessee shops “wouldn’t produce the doomsday state of affairs they declare that it’s going to,” mentioned McKinney. “But when the invoice ignites curiosity throughout the county or if there’s federal laws, that might be an issue for them.”
This story initially appeared in STAT’s sister publication, The Boston Globe.